Breast Cancer | Specialty

Frontline Therapy in HR-Positive Breast Cancer

July 12th 2018

Therapy Approaches in HR+ Breast Cancer

July 12th 2018

Optimal Duration of Adjuvant Endocrine Therapy Undecided in ER+ Breast Cancer

July 10th 2018

Maryann J. Kwa, MD, discusses the optimal duration of endocrine therapy in the treatment of patients with early-stage ER-positive breast cancer.

Expert Sheds Light on Adjuvant Treatment of HR+ Breast Cancer

July 9th 2018

Michael A. Savin, MD, shares his insight on adjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer.

Optimal Use With Adjuvant Endocrine Therapy Continues to Unfold in ER+ Breast Cancer

July 9th 2018

Alex E. Denes, MD, discusses the mixed results looking at the optimal duration of adjuvant endocrine therapy in postmenopausal women with breast cancer.

Dr. Esteva on the Impact of the Trastuzumab Biosimilar Approval

July 7th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses the impact of the approval of the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst).

CDK4/6 Inhibitors Continue to Offer Hope in Breast Cancer

July 6th 2018

Jacqueline Vuky, MD, discusses the management of metastatic disease and CDK4/6 inhibitors in breast cancer.

Expert Highlights Ongoing Efforts for TNBC Treatment

July 6th 2018

David B. Page, MD, discusses emerging treatment approaches for patients with triple-negative breast cancer.

Dr. Kwa on the TAILORx Trial in Breast Cancer

July 5th 2018

Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the results of the TAILORx trial in breast cancer.

Dr. Adams on Immunotherapy in Triple-Negative Breast Cancer

July 3rd 2018

Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, New York University Langone’s Perlmutter Cancer Center, discusses immunotherapy in triple-negative breast cancer (TNBC).

Frontline Atezolizumab/Nab-Paclitaxel Improves PFS in Phase III TNBC Trial

July 2nd 2018

Upfront treatment with atezolizumab plus nab-paclitaxel significantly reduced the risk of disease progression or death compared with nab-paclitaxel alone in patients with metastatic or unresectable locally advanced triple-negative breast cancer.

ACR and SBI Recommend Universal Breast Cancer Risk Assessment at Age 30

June 29th 2018

New breast cancer screening guidelines from the American College of Radiology and Society of Breast Imaging advise all women to undergo risk assessment at age 30, followed by screening for those with a greater chance of cancer.

Dr. Mitri on the Treatment Landscape of HER2+ Breast Cancer

June 29th 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the treatment landscape of HER2-positive breast cancer.

Approaches to Postmastectomy Breast Reconstruction Are Evolving

June 28th 2018

Emerging evidence shows that immediate autologous breast reconstruction can tolerate radiotherapy better than previously thought in select cases.

ASTRO Guidelines Support Accelerated Whole Breast Radiation for Most Patients

June 28th 2018

A new American Society for Radiation Oncology guideline calls for hypofractionated whole breast irradiation for patients with breast cancer regardless of age, tumor stage, and previous chemotherapy treatment.

Dr. McCann on Ongoing Research in HER2-Positive Breast Cancer

June 27th 2018

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses ongoing research in the field of HER2-positive breast cancer.

Dr. Gerber on Advances in Radiation Oncology in Breast Cancer

June 27th 2018

Naamit K. Gerber, MD, assistant professor, Department of Radiation Oncology, NYU Langone’s Perlmutter Cancer Center, discusses advances in radiation oncology in the treatment of patients with breast cancer.

Palbociclib Misses OS Endpoint in PALOMA-3 Breast Cancer Study

June 25th 2018

The combination of palbociclib (Ibrance) and fulvestrant (Faslodex) failed to improve overall survival compared with fulvestrant and placebo in the phase III PALOMA-3 trial for patients with HR-positive, HER2-negative metastatic breast cancer.

Breast Cancer Stem Cell Research Burgeoning With Vaccines, Epigenetic Therapeutic Developments

June 21st 2018

Max Wicha, MD, shares insight on the intriguing research being conducted on breast cancer stem cells.

Evolution of Genetic Testing in Breast Cancer Continues

June 21st 2018

Michael Simon, MD, MPH, discusses advances in genetic testing for breast cancer, highlighting the overlap between genomic risk assessment and tumor genomic profiling.